Navigation Links
VaxGen Files First Quarter 2007 Financials
Date:9/21/2007

SOUTH SAN FRANCISCO, Calif., Sept. 21 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that it has filed with the Securities and Exchange Commission (SEC) its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. The report can be found at the link titled "SEC Filings" in the Investor Relations section of VaxGen's web site at http://www.vaxgen.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

The only financial statements the company has outstanding before it regains compliance with its SEC financial reporting obligations are the Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, which is currently under review by VaxGen and its independent auditors. Once VaxGen is current with its financial statements, the company intends to apply for listing on a national stock exchange.

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the anticipated filing of the company's outstanding quarterly reports and its application for listing of its common stock. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. PCR Polymerases Application Profiles
2. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Successful stabilization of gene expression profiles
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Third Wave files countersuit vs. Digene in patent case
7. TomoTherapy files registration statement for IPO
8. Merge files financial reports by market opening
9. The Why Files celebrates decade of science exploration
10. Third Wave files patent suits against Digene, Chiron and Bayer
11. New Web virus could lead to lost files, extortion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... ... 2017 , ... Sonic Manufacturing Technologies is proud to be ... solar system on its roof top. “We will be independent of the grid ... stated. The company’s proud history of social responsibility and participation in the preservation ...
(Date:7/14/2017)... ... July 13, 2017 , ... ... verification test kit has received US FDA 510 (k) clearance for use on ... matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal ...
(Date:7/13/2017)... ... ... Thousands of pilots from across the country will visit the AMA’s International ... to Muncie to compete in various categories of model flying competition. Each pilot comes ... championships. , RC Pylon (July 14-21): One of the most fun competitions to watch! ...
(Date:7/13/2017)... ... 2017 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), the ... of a major transaction with Eurazeo PME. The reputable French private equity comes ... In’Tech Medical’s service offerings while leveraging the company’s manufacturing expertise and global footprint. ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):